Scientific Publications

PD-1/PD-L1 Interaction Predicts Survival in NSCLC

188 patients. High interaction: 31 months OS vs 10 months (P<0.0001). PD-L1 expression did NOT predict (P=0.162).

Combined CTLA-4/CD80 and PD-1/PD-L1 Checkpoint Biomarkers

"Double high" patients: 35 months OS. Neither biomarker predicted chemo response—ICI-specific.

PKB/Akt Activation Predicts Survival in ccRCC

Activation: HR=0.228, P=0.002. Expression: HR=1.390, P=0.548. Function predicts; expression does not.

iFRET for PD-1/PD-L1 in Melanoma and NSCLC

Established two-site cell-cell amplified FRET methodology. High interaction correlates with anti-PD-1 response.

Checkpoint Interactions in RFA-Treated Lung Metastases

First CTLA-4/CD80 quantification at 1-10nm resolution. Interaction did NOT correlate with expression.

TR-FRET/FLIM for Predictive Biomarkers in Oncology

Comprehensive review covering PKC, Akt/PKB, HER2-HER3, PD-1/PD-L1 applications.

Commentary: iFRET Predicts Patient Outcomes

Perspective on iFRET methodology and implications for precision oncology biomarkers.